NCT00572364View on ClinicalTrials.gov

Open Label, Dose Escalation Phase I Study of AZD2281

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

Advanced Solid Malignancies

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

Trial Locations (1)

Unknown

Research Site, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY